The myth of 'stable' coronary artery disease.
Journal
Nature reviews. Cardiology
ISSN: 1759-5010
Titre abrégé: Nat Rev Cardiol
Pays: England
ID NLM: 101500075
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
accepted:
24
06
2019
pubmed:
31
7
2019
medline:
6
2
2020
entrez:
31
7
2019
Statut:
ppublish
Résumé
Patients with known cardiovascular disease who have not had a recent acute event are often referred to as having stable coronary artery disease (CAD). The concept of 'stable' CAD is misleading for two important reasons: the continuing risks of cardiovascular events over the longer term and the diverse spectrum of powerful risk characteristics. The risks of cardiovascular events are frequently underestimated and continue to exist, despite current standards of care for secondary prevention, including lifestyle changes, optimal medical therapy, myocardial revascularization and the use of antiplatelet agents to limit thrombosis. In dispelling the myth of 'stable' CAD, we explore the pathophysiology of the disease and the relative contribution of plaque and systemic factors to cardiovascular events. A broader concept of the vulnerable patient, not just the vulnerable plaque, takes into account the diversity and future risks of atherothrombotic events. We also evaluate new and ongoing research into medical therapies aimed at further reducing the risks of cardiovascular events in patients with chronic - but not stable - atherothrombotic disease.
Identifiants
pubmed: 31358978
doi: 10.1038/s41569-019-0233-y
pii: 10.1038/s41569-019-0233-y
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
9-21Références
Montalescot, G. et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur. Heart J. 34, 2949–3003 (2013).
pubmed: 23996286
Bonaca, M. P. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl. J. Med. 372, 1791–1800 (2015).
pubmed: 25773268
Morrow, D. A. et al. Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med. 366, 1404–1413 (2012).
pubmed: 22443427
Connolly, S. J. et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 391, 205–218 (2018).
pubmed: 29132879
Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).
pubmed: 28845751
pmcid: 28845751
Cannon, C. P. et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372, 2387–2397 (2015).
pubmed: 26039521
Clayton, T. C. et al. Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients. BMJ 331, 869 (2005).
pubmed: 16210253
pmcid: 1255789
Falk, E., Nakano, M., Bentzon, J. F., Finn, A. V. & Virmani, R. Update on acute coronary syndromes: the pathologists’ view. Eur. Heart J. 34, 719–728 (2013).
pubmed: 23242196
Libby, P. & Theroux, P. Pathophysiology of coronary artery disease. Circulation 111, 3481–3488 (2005).
pubmed: 15983262
Arbab-Zadeh, A. & Fuster, V. The myth of the “vulnerable plaque”: transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment. J. Am. Coll. Cardiol. 65, 846–855 (2015).
pubmed: 25601032
pmcid: 4344871
Bhatt, D. L. et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295, 180–189 (2006).
pubmed: 16403930
Kubo, T. et al. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J. Am. Coll. Cardiol. 50, 933–939 (2007).
pubmed: 17765119
Xu, Y. et al. Prevalence, distribution, predictors, and outcomes of patients with calcified nodules in native coronary arteries: a 3-vessel intravascular ultrasound analysis from Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT). Circulation 126, 537–545 (2012).
pubmed: 22744975
Virmani, R., Kolodgie, F. D., Burke, A. P., Farb, A. & Schwartz, S. M. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 20, 1262–1275 (2000).
pubmed: 10807742
Stone, G. W. et al. A prospective natural-history study of coronary atherosclerosis. N. Engl. J. Med. 364, 226–235 (2011).
pubmed: 21247313
Libby, P., Pasterkamp, G., Crea, F. & Jang, I. K. Reassessing the mechanisms of acute coronary syndromes: the “vulnerable plaque” and superficial erosion. Circ. Res. 124, 150–160 (2019).
pubmed: 30605419
Yeh, R. W. et al. Population trends in the incidence and outcomes of acute myocardial infarction. N. Engl. J. Med. 362, 2155–2165 (2010).
pubmed: 20558366
McManus, D. D. et al. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am. J. Med. 124, 40–47 (2011).
pubmed: 21187184
pmcid: 3011975
Murugiah, K., Nuti, S. V. & Krumholz, H. M. STEMI care in LMIC: obstacles and opportunities. Glob. Heart 9, 429–430 (2014).
Murugiah, K. et al. Are non-ST-segment elevation myocardial infarctions missing in China? Eur. Heart. J. Qual. Care Clin. Outcomes 3, 319–327 (2017).
Naghavi, M. et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 108, 1664–1672 (2003).
pubmed: 14530185
Asakura, M. et al. Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: an angioscopic study. J. Am. Coll. Cardiol. 37, 1284–1288 (2001).
pubmed: 11300436
Burke, A. P. et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 103, 934–940 (2001).
pubmed: 11181466
Kubo, T. et al. The dynamic nature of coronary artery lesion morphology assessed by serial virtual histology intravascular ultrasound tissue characterization. J. Am. Coll. Cardiol. 55, 1590–1597 (2010).
pubmed: 20378076
Ali, Z. A. et al. Intracoronary optical coherence tomography 2018: current status and future directions. JACC Cardiovasc. Interv. 10, 2473–2487 (2017).
pubmed: 29268880
Tarkin, J. M., Joshi, F. R., Rajani, N. K. & Rudd, J. H. PET imaging of atherosclerosis. Future Cardiol. 11, 115–131 (2015).
pubmed: 25606707
Irkle, A. et al. Identifying active vascular microcalcification by
pubmed: 26151378
pmcid: 4506997
Buysschaert, I. et al. A variant at chromosome 9p21 is associated with recurrent myocardial infarction and cardiac death after acute coronary syndrome: the GRACE Genetics Study. Eur. Heart J. 31, 1132–1141 (2010).
pubmed: 20231156
pmcid: 2862180
Adamson, P. D. et al. High-sensitivity cardiac troponin I and the diagnosis of coronary artery disease in patients with suspected angina pectoris. Circ. Cardiovasc. Qual. Outcomes 11, e004227 (2018).
pubmed: 29444926
pmcid: 5837016
Januzzi, J. L. Jr. et al. High-sensitivity troponin I and coronary computed tomography in symptomatic outpatients with suspected coronary artery disease: insights from the PROMISE trial. JACC Cardiovasc. Imaging 12, 1047–1055 (2018).
pubmed: 29550314
Lindholm, D. et al. Biomarker-based risk model to predict cardiovascular mortality in patients with stable coronary disease. J. Am. Coll. Cardiol. 70, 813–826 (2017).
pubmed: 28797349
Thomas, M. R. & Lip, G. Y. H. Novel risk markers and risk assessments for cardiovascular disease. Circ. Res. 120, 133–149 (2017).
pubmed: 28057790
Park, K. C., Gaze, D. C., Collinson, P. O. & Marber, M. S. Cardiac troponins: from myocardial infarction to chronic disease. Cardiovasc. Res. 113, 1708–1718 (2017).
pubmed: 29016754
pmcid: 5852618
Smith, S. C. Jr et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 124, 2458–2473 (2011).
pubmed: 22052934
Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).
pubmed: 26378978
Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657 (2017).
pubmed: 28605608
Catapano, A. L. et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Rev. Esp. Cardiol. 70, 115 (2017).
pubmed: 29389351
Fihn, S. D. et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 126, e354–e471 (2012).
pubmed: 23166211
Vaccarino, V. et al. Depression and coronary heart disease: 2018 ESC position paper of the working group of coronary pathophysiology and microcirculation developed under the auspices of the ESC Committee for Practice Guidelines. Eur. Heart J. https://doi.org/10.1093/eurheartj/ehy913 (2019).
doi: 10.1093/eurheartj/ehy913
pubmed: 31713592
Windecker, S. et al. 2014 ESC/EACTS guidelines on myocardial revascularization. EuroIntervention 10, 1024–1094 (2015).
pubmed: 25187201
Katritsis, D. G., Mark, D. B. & Gersh, B. J. Revascularization in stable coronary disease: evidence and uncertainties. Nat. Rev. Cardiol. 15, 408–419 (2018).
pubmed: 29654257
Valgimigli, M. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 39, 213–260 (2018).
pubmed: 28886622
Eikelboom, J. W. et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N. Engl. J. Med. 377, 1319–1330 (2017).
pubmed: 28844192
Steg, P. G. et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297, 1197–1206 (2007).
pubmed: 17374814
Jernberg, T. et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur. Heart J. 36, 1163–1170 (2015).
pubmed: 25586123
SCOT-HEART Investigators et al. Coronary CT angiography and 5-year risk of myocardial infarction. N. Engl. J. Med. 379, 924–933 (2018).
Rapsomaniki, E. et al. Prognostic models for stable coronary artery disease based on electronic health record cohort of 102 023 patients. Eur. Heart J. 35, 844–852 (2014).
pubmed: 24353280
Rapsomaniki, E. et al. Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction. Eur. Heart J. Qual. Care Clin. Outcomes 2, 172–183 (2016).
pubmed: 29474617
pmcid: 5815620
Sachdev, M. et al. The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease. J. Am. Coll. Cardiol. 43, 576–582 (2004).
pubmed: 14975466
Eisen, A. et al. Angina and future cardiovascular events in stable patients with coronary artery disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. J. Am. Heart Assoc. 5, e004080 (2016).
pubmed: 27680665
pmcid: 5121505
Yeo, K. K. et al. Comparative analysis of recurrent events after presentation with an index myocardial infarction or ischemic stroke. Eur. Heart J. Qual. Care Clin. Outcomes 3, 234–242 (2016).
Fox, K. A. A. et al. Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. Nat. Clin. Pract. Cardiovasc. Med. 5, 580–589 (2008).
pubmed: 18665136
Ringleb, P. A. et al. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 35, 528–532 (2004).
pubmed: 14739421
Bhatt, D. L. et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 304, 1350–1357 (2010).
pubmed: 20805624
O’Donoghue, M. L. et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 312, 1006–1015 (2014).
pubmed: 25173516
Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322 (2016).
pubmed: 27295427
pmcid: 4985288
Holman, R. R. et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 377, 1228–1239 (2017).
pubmed: 28910237
Suarez, C. et al. Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry. Vasc. Med. 15, 259–265 (2010).
pubmed: 20724374
Bansilal, S. et al. Ticagrelor for secondary prevention of atherothrombotic events in patients with multivessel coronary disease. J. Am. Coll. Cardiol. 71, 489–496 (2018).
pubmed: 29406853
Wilson, P. W. et al. An international model to predict recurrent cardiovascular disease. Am. J. Med. 125, 695–703 (2012).
pubmed: 22727237
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348, 1329–1339 (1996).
Bhatt, D. L. et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 103, 363–368 (2001).
pubmed: 11157686
Kosova, E. C. et al. Vorapaxar in patients with coronary artery bypass grafting: findings from the TRA 2°P-TIMI 50 trial. Eur. Heart J. Acute Cardiovasc. Care 6, 164–172 (2017).
pubmed: 27075924
Yap, C. H. et al. Contemporary results show repeat coronary artery bypass grafting remains a risk factor for operative mortality. Ann. Thorac Surg. 87, 1386–1391 (2009).
pubmed: 19379870
Cavender, M. A. et al. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) registry. Circulation 132, 923–931 (2015).
pubmed: 26152709
Virmani, R., Burke, A. P. & Kolodgie, F. Morphological characteristics of coronary atherosclerosis in diabetes mellitus. Can. J. Cardiol. 22 (Suppl. B), 81B–84B (2006).
pubmed: 16498517
pmcid: 2780829
Bhatt, D. L. et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am. J. Cardiol. 90, 625–628 (2002).
pubmed: 12231089
Cavender, M. A. et al. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 trial. Circulation 131, 1047–1053 (2015).
pubmed: 25681464
pmcid: 4365950
Brooks, M. M. et al. Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation 126, 2115–2124 (2012).
pubmed: 23008442
pmcid: 4104411
Dumaine, R. L. et al. Renal function, atherothrombosis extent, and outcomes in high-risk patients. Am. Heart J. 158, 141–148 (2009).
pubmed: 19540404
Kalra, P. R. et al. Impact of chronic kidney disease on use of evidence-based therapy in stable coronary artery disease: a prospective analysis of 22,272 patients. PLOS ONE 9, e102335 (2014).
pubmed: 25051258
pmcid: 4106833
Hill, N. R. et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. PLOS ONE 11, e0158765 (2016).
pubmed: 27383068
pmcid: 4934905
Cai, Q., Mukku, V. K. & Ahmad, M. Coronary artery disease in patients with chronic kidney disease: a clinical update. Curr. Cardiol. Rev. 9, 331–339 (2013).
pubmed: 24527682
pmcid: 3941098
Briasoulis, A. & Bakris, G. L. Chronic kidney disease as a coronary artery disease risk equivalent. Curr. Cardiol. Rep. 15, 340 (2013).
pubmed: 23338722
Bernaudo, D. et al. Renal function and short-term outcome in stable outpatients with coronary, cerebrovascular or peripheral artery disease. Atherosclerosis 229, 258–262 (2013).
pubmed: 23714334
Magnani, G. et al. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. Eur. Heart J. 37, 400–408 (2016).
pubmed: 26443023
Gheorghiade, M. et al. Navigating the crossroads of coronary artery disease and heart failure. Circulation 114, 1202–1213 (2006).
pubmed: 16966596
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390, 1211–1259 (2017).
Gheorghiade, M. et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296, 2217–2226 (2006).
pubmed: 17090768
Seferovic, P. M. et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 20, 853–872 (2018).
pubmed: 29520964
Jensen, L. O. et al. Influence of diabetes mellitus on clinical outcomes following primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Am. J. Cardiol. 109, 629–635 (2012).
pubmed: 22152969
Ritsinger, V., Saleh, N., Lagerqvist, B. & Norhammar, A. High event rate after a first percutaneous coronary intervention in patients with diabetes mellitus: results from the Swedish coronary angiography and angioplasty registry. Circ. Cardiovasc. Interv. 8, e002328 (2015).
pubmed: 26025219
Weitz, J. I. Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome. Thromb. Haemost. 112, 924–931 (2014).
pubmed: 25030773
Casa, L. D., Deaton, D. H. & Ku, D. N. Role of high shear rate in thrombosis. J. Vasc. Surg. 61, 1068–1080 (2015).
pubmed: 25704412
Bhatt, D. L. et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354, 1706–1717 (2006).
pubmed: 16531616
Bhatt, D. L. et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J. Am. Coll. Cardiol. 49, 1982–1988 (2007).
pubmed: 17498584
Hirsh, J. & Bhatt, D. L. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch. Intern. Med. 164, 2106–2110 (2004).
pubmed: 15505123
Bhatt, D. L. et al. Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54. J. Am. Coll. Cardiol. 67, 2732–2740 (2016).
pubmed: 27046160
Magnani, G. et al. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. Eur. J. Heart Fail. 18, 1153–1161 (2016).
pubmed: 27349698
Rothberg, M. B., Celestin, C., Fiore, L. D., Lawler, E. & Cook, J. R. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann. Intern. Med. 143, 241–250 (2005).
pubmed: 16103468
Testa, L. et al. Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes. Am. J. Cardiol. 99, 1637–1642 (2007).
pubmed: 17560866
Alexander, J. H. et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N. Engl. J. Med. 365, 699–708 (2011).
pubmed: 21780946
Mega, J. L. et al. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. 366, 9–19 (2012).
pubmed: 22077192
Ohman, E. M. et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet 389, 1799–1808 (2017).
pubmed: 28325638
Stachon, P., Ahrens, I., Bode, C. & Zirlik, A. Dual pathway therapy in acute coronary syndrome. J. Thromb. Thrombolysis 42, 254–260 (2016).
pubmed: 26660521
European Medicines Agency. Annex I: summary of product characteristics. EMA http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf (2018).
Janssen Pharmaceuticals. Xarelto® (rivaroxaban): highlights of prescribing information. Janssen http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf (2019).
Dewilde, W. J. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381, 1107–1115 (2013).
pubmed: 23415013
US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT03234114 (2018).
US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02567461 (2018).
US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02548650 (2019).
Anand, S. S. et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 391, 219–229 (2018).
pubmed: 29132880
Darmon, A. et al. External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. Eur. Heart J. 39, 750–757a (2018).
Bai, J., Gong, L. L., Li, Q. F. & Wang, Z. H. Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: a meta-analysis of 11 randomized controlled trials. J. Clin. Lipidol. 12, 277–291 (2018).
pubmed: 29428832
Silverman, M. G. et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 316, 1289–1297 (2016).
pubmed: 27673306
Schiele, F. et al. A consensus statement on lipid management after acute coronary syndrome. Eur. Heart J. Acute Cardiovasc. Care 7, 532–543 (2018).
pubmed: 27856518
Ridker, P. M. et al. Low-dose methotrexate for the prevention of atherosclerotic events. N. Engl. J. Med. 380, 752–762 (2019).
pubmed: 30415610
Kaul, S. Mitigating cardiovascular risk in type 2 diabetes with antidiabetes drugs: a review of principal cardiovascular outcome results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 trials. Diabetes Care 40, 821–831 (2017).
pubmed: 28637887
Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834–1844 (2016).
pubmed: 27633186
Bobadilla, R. V. Acute coronary syndrome: focus on antiplatelet therapy. Crit. Care Nurse 36, 15–27 (2016).
pubmed: 26830177
Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373, 1849–1860 (2009).
Fox, K. A. A. et al. Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add? Eur. Heart J. 40, 1466–1471 (2018).
Steg, P. G. et al. Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International Observational CLARIFY registry. JAMA. Intern. Med. 174, 1651–1659 (2014).
Steg, P. G. et al. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. Eur. Heart J. 33, 2831–2840 (2012).
pubmed: 22922505
pmcid: 3498005
Fox, K. A. A. et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open 4, e004425 (2014).
pubmed: 24561498
pmcid: 3931985
Saar, A. et al. The risk-treatment paradox in non-ST-elevation myocardial infarction patients according to their estimated GRACE risk. Int. J. Cardiol. 272, 26–32 (2018).
pubmed: 30121176
Bohula, E. A. et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. J. Am. Coll. Cardiol. 69, 911–921 (2017).
pubmed: 28231942